To study the influence of physical inactivity, induced by leg immobilization, on muscle charateristics, satellite cell content and muscle protein synthesis rate.
ID
Source
Brief title
Condition
- Muscle disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Muscle charateristics and satellite cell content, at 0, 2 and 8 weeks after the
start of the intervention.
In addition, muscle protein synthesis rate will be determined at 0 en 2 wks.
Secondary outcome
Maximal strength
Cross-sectional area of the upper leg
Background summary
Aging is characterized by a decrease in skeletal muscle mass and strength, also
known as sarcopenia. This age-related reduction in muscle mass and strength is
associated with a decline in muscle function and performance. On a myocellular
level, sarcopenia is characterized by a reduction in muscle fiber number and
size, with specific type II muscle fiber atrophy. The age-related reduction in
type II muscle fiber size is accompanied by a type II muscle fiber specific
decline in satellite cell (muscle stem cell) content. In adult muscle,
satellite cells are essential for myofiber growth, repair and regeneration.
Thus, the reduction in satellite cell content with age could play an important
role in the development of sarcopenia. In addition, apart from the essential
role that SC play in the maintenance of skeletal muscle mass, day to day
regulation of muscle mass is governed by an intricate balance between muscle
protein synthesis and muscle protein breakdown . Of these, muscle protein
synthesis has been shown to be the most susceptible to change. While basal
muscle protein synthesis does not seem to change with age, it is now becoming
apparent that the normal stimulation of muscle protein synthesis in response to
feeding may become impaired with age. Thus, muscle loss with aging is likely to
be a combination of the decline in SC number and/or the reduced stimulation of
muscle protein synthesis to food.
In the present study we will investigate the effects of physical inactivity,
induced by leg immobilization, on muscle characteristics and satellite cell
content in healthy, young males. The latter can give further insight into the
role of satellite cells in inactivity induced muscle fiber atrophy and/or
sarcopenia.
Study objective
To study the influence of physical inactivity, induced by leg immobilization,
on muscle charateristics, satellite cell content and muscle protein synthesis
rate.
Study design
During this study we will follow participants for a time period of 8 weeks.
Following the first test day one leg will be immobilized by means of a cast,
for a time period of 2 weeks. After 2 weeks of immobilization (on the second
test day), the leg cast will be removed. On this test day we will assess the
effects of the immobilization period. Finally, the third test day will be 6
weeks after cast removal, to assess the effects natural recovery.
Intervention
The intervention period is 2 weeks. During this period 1 leg will be
immobilized by means of a leg cast.
Study burden and risks
At the site of the muscle biopsy a hematoma could occur. The muscle biopsy is
performed by an experienced physician. The incision made for obtaining the
muscle biopsy will heal completely. The biopsy scare will be assessed by a
physician before the leg is casted. The immobilization period will lead to loss
of muscle mass and strength in the immobilized leg. However, previous research
has shown that this loss of muscular strength returns to pre-immobilized values
within weeks after removal of the cast, without specific training. The
radiation from the CT-scan is negligible becasue only one image ("single-slice)
is taken and this on 0, 2 and 8 weeks of the intervention
postbus 616
6200 MD Maastricht
Nederland
postbus 616
6200 MD Maastricht
Nederland
Listed location countries
Age
Inclusion criteria
Male
Age between 18 and 35 years old
BMI <= 30
Exclusion criteria
Use of medication that may affect haemostasis
Subjects with (recent) musculoskeletal/orthopaedic disorders known to affect the outcome of the study or that compromise their ability to walk with crutches.
Subjects with metal implants in their lower limbs
Subjects with known current cardiovascular disease
Subjects with cardiovascular disease in their history
Subjects with known current haemostatic disorders
Subjects with haemostatic disorders in their history;Previously experienced side effects of heparine-like coagulant medication
Blood loss from tractus digestivus (ulcus pepticum, tumor, hiatus hernia or diverticulosis)
Surgery of cerebrum, eyes or spinal cord during fraxiparine application period
Lumbar puncture during fraxiparine application period
Anaesthesia (regional or spinal) during fraxiparine application period
Renal dysfunction
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
ClinicalTrials.gov | NCT00936039 |
CCMO | NL27212.068.09 |